首頁 > 市場調查報告書 > 製藥

再生醫學

市場調查報告書

商品編碼

1940465

幹細胞與再生醫學：全球市場

Stem Cell and Regenerative Therapy: Global Markets

出版日期: 2026年02月09日 | 出版商:

BCC Research | 英文 168 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球幹細胞和再生醫學市場預計將從 2025 年的 167 億美元成長到 2030 年的 438 億美元，2025 年至 2030 年的複合年成長率為 21.3%。

預計北美市場將從 2025 年的 67 億美元成長到 2030 年的 174 億美元，2025 年至 2030 年的複合年成長率為 21.2%。

預計亞太市場規模將從 2025 年的 35 億美元成長到 2030 年的 101 億美元，2025 年至 2030 年的複合年成長率為 23.2%。

本報告調查了全球幹細胞和再生醫學市場，並提供了市場概況、市場影響因素和市場機會分析、技術趨勢、法律制度、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

技術背景
幹細胞
胚胎幹細胞
成體幹細胞
間質幹細胞
造血幹細胞
神經幹細胞
前驅細胞
上皮幹細胞
超小型胚胎樣細胞
臍帶血幹細胞
誘導性多功能細胞
細胞療法
CAR-T細胞療法簡史
FDA產品核可
基因治療
基因治療的發展
宏觀經濟因素分析
PESTEL 分析
美國關稅立法對幹細胞和再生醫學市場的影響
波特五力分析

第3章市場動態

市場動態
市場促進因素
對再生醫學的需求日益成長
組織工程產品的研究和監管核准不斷增加
創業投資資金籌措增加
對高效藥物發現和開發過程的需求
人們越來越關注如何最大限度地減少動物試驗
市場限制
高成本和熟練勞動力短缺
複雜的法規結構
市場機遇
技術進步
iPSC銀行的發展

第4章：監理現狀

概述
基因治療監管
細胞治療法規
病毒載體和非病毒載體
培養基
美國法規結構
歐洲法規結構
歐洲細胞和基因治療監管
亞太地區法規結構

第5章新興科技與新發展

概述
再程式化技術
基因編輯技術
3D類器官
人工智慧在幹細胞研究的應用

第6章市場區隔分析

細分市場分析
市場區隔：依產品/服務分類
重點總結
治療藥物
工具和試劑
細胞庫
市場區隔：按應用領域
重點總結
瘤
整形外科
糖尿病
皮膚科
心血管疾病
中樞神經系統疾病
其他
地理細分
市場區隔：依地區分類
重點總結
北美洲
歐洲
亞太地區
世界其他地區

第7章競爭訊息

重點總結
2024年資本利得稅市場的主要企業
組織工程市場的主要企業
戰略分析

8. 幹細胞與再生醫學市場的永續性：ESG視角

永續性：幹細胞和再生醫學市場
了解ESG數據
主要ESG問題
環境績效
社會表現
管治績效
BCC 的結論

第9章：專利現狀

重點總結
專利審查
基因療法專利（按年份）
基因治療專利（由主要申請人提交）
基因治療專利（依文件類型）
細胞療法專利（按年份）
細胞療法專利（由主要申請人提出）
細胞療法專利（按狀態）
組織工程專利（按年份）
組織工程專利（由主要申請人提出）
組織工程專利（按狀態）

第10章附錄

調查方法
簡稱
參考
公司簡介
ABBVIE INC.
AMGEN INC.
BIOGEN
BLUEBIRD BIO INC. (GENETIX BIOTHERAPEUTICS INC.)
BRISTOL-MYERS SQUIBB CO.
CELLECTIS SA
CRISPR THERAPEUTICS
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
MIMEDX GROUP INC.
NOVARTIS AG
ORGANOGENESIS INC.
STRYKER
TECNOSS
ZIMMER BIOMET

簡介目錄圖表

Product Code: BIO191B

The global market for stem cell and regenerative therapy is projected to grow from an estimated $16.7 billion in 2025 to $43.8 billion by 2030, at a compound annual growth rate (CAGR) of 21.3% from 2025 to 2030.

The North American market for stem cell and regenerative therapy is projected to grow from an estimated $6.7 billion in 2025 to $17.4 billion by 2030, at a CAGR of 21.2% from 2025 to 2030.

The Asia-Pacific market for stem cell and regenerative therapy is projected to grow from an estimated $3.5 billion in 2025 to $10.1 billion by 2030, at a CAGR of 23.2% from 2025 to 2030.

Report Scope

The report provides an overview of the global stem cell and regenerative therapy market and analyzes market trends. The report includes global revenue (in $ millions) for the base year data (2024) and estimated data for the forecast period (2025 through 2030). The market is segmented by product and services, application and region. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with a focus on major countries in each region.

The report focuses on significant trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies and the patent landscape related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking or share of key companies in the global stem cell and regenerative medicine market, as well as a patent analysis. It also features a section with company profiles that provides overviews, key financials, product portfolios and recent developments of key market companies.

Report Includes

50 data tables and 62 additional tables
Overview and an analysis of the global market for stem cell and regenerative therapy (medicines)
Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
Estimates of the current market size and revenue prospects of the global market, along with a corresponding market share analysis based on product and service type, application and region
Facts and figures pertaining to global market dynamics, advancements in therapy, regulations, prospects and the impact of macroeconomic factors
Insights derived from Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Patent review, featuring key granted and published patents
Review of emerging trends and technologies as well as new developments in the stem cell and regenerative therapy market
Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives and venture fundings, and an investment outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
Profiles of the leading companies, including Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb Co., Organogenesis Inc., and MiMedx Group Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Technology Background
Stem Cell
Embryonic Stem Cells
Adult Stem Cells
Mesenchymal Stem Cells
Hematopoietic Stem Cells
Neural Stem Cell
Endothelial Progenitor Cell
Epithelial Stem Cell
Very Small Embryonic-Like Cell
Cord Blood Stem Cell
Induced Pluripotent Stem Cells
Cell Therapy
A Brief History of CAR-T Cell Therapy
FDA Product Approvals
Gene Therapy
Evolution of Gene Therapy
Macroeconomic Factors Analysis
PESTEL Analysis
Impact of U.S. Tariff Laws on the Stem Cell and Regenerative Therapy Market
Porter's Five Forces Analysis
Potential for New Entrants (Moderate to High)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (High)
Threat of Substitutes (Low to Moderate)
Competition in the Industry (High)

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Growing Demand for Regenerative Medicines
Increasing Research and Regulatory Approval for Tissue Engineering Products
Rising Venture Capital Funding
Demand for an Effective Drug Discovery and Development Process
Rising Focus on Minimizing Animal Testing
Market Restraints
High Cost and Lack of Skilled Workforce
Complex Regulatory Framework
Market Opportunities
Technological Advances
Growth in iPSC Banking

Chapter 4 Regulatory Landscape

Overview
Gene Therapy Regulations
Cell Therapy Regulations
Viral and Non-Viral Vectors
Media
Regulatory Frameworks in the U.S.
Regulatory Frameworks in Europe
Cell and Gene Therapy Regulations in Europe
Regulatory Frameworks in Asia-Pacific

Chapter 5 Emerging Technologies and New Developments

Overview
Reprogramming Technologies
Gene Editing Technologies
3D Organoids
Artificial Intelligence in Stem Cell Research

Chapter 6 Market Segment Analysis

Segmentation Breakdown
Market Breakdown by Products and Services
Key Takeaways
Therapeutics
Tools and Reagents
Cell Banking
Market Breakdown by Application
Key Takeaways
Oncology
Orthopedic
Diabetes
Dermatology
Cardiovascular Disorders
Central Nervous System Disorders
Others
Geographic Breakdown
Market Breakdown by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Key Takeaways
Leading Players in the CGT Market, 2024
Leading Players in the Tissue Engineering Market, 2024
Strategic Analysis

Chapter 8 Sustainability in the Stem Cell and Regenerative Therapy Market: ESG Perspective

Sustainability: The Stem Cell and Regenerative Therapy Market
Understanding the ESG Data
Key ESG Issues
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC

Chapter 9 Patent Landscape

Key Takeaways
Patent Review
Gene Therapy Patents, by Year
Gene Therapy Patents, by Leading Applicants
Gene Therapy Patents, by Document Type
Cell Therapy Patents, by Year
Cell Therapy Patents, by Leading Applicants
Cell Therapy Patents, by Status
Tissue Engineering Patents, by Year
Tissue Engineering Patents, by Leading Applicants
Tissue Engineering Patents, by Status

Chapter 10 Appendix

Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
AMGEN INC.
BIOGEN
BLUEBIRD BIO INC. (GENETIX BIOTHERAPEUTICS INC.)
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
CRISPR THERAPEUTICS
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
MIMEDX GROUP INC.
NOVARTIS AG
ORGANOGENESIS INC.
STRYKER
TECNOSS
ZIMMER BIOMET

簡介目錄圖表

List of Tables

Summary Table : Global Market for Stem Cell and Regenerative Therapy, by Region, Through 2030
Table 1 : U.S. FDA-Approved CAR-T Cell Therapies
Table 2 : Tissue Engineering and Regeneration: Venture Capital Funding, 2024
Table 3 : Tissue Engineering and Regeneration: Pricing
Table 4 : Tissue Engineering and Regeneration: Regulatory Overview, 2025
Table 5 : Brief Information on iPSC Repositories
Table 6 : Asia-Pacific: Regulatory Landscape, 2024
Table 7 : Global Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 8 : Global Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 9 : Global Market for Stem Cell and Regenerative Therapy for Therapeutics, by Region, Through 2030
Table 10 : Global Market for Stem Cell and Regenerative Therapy for Cell Therapy, by Region, Through 2030
Table 11 : FDA-Approved Cell-Based Immunotherapy Products
Table 12 : Approved Human Gene Therapy Products
Table 13 : Global Market for Stem Cell and Regenerative Therapy for Gene Therapy, by Region, Through 2030
Table 14 : Global Market for Stem Cell and Regenerative Therapy for Tissue Engineering, by Region, Through 2030
Table 15 : Recently Launched Stem Cell Reagents, 2024 and 2025
Table 16 : Global Market for Stem Cell and Regenerative Therapy for Tools and Reagents, by Region, Through 2030
Table 17 : Global Market for Stem Cell and Regenerative Therapy for Cell Banking, by Region, Through 2030
Table 18 : Global Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 19 : Global Market for Stem Cell and Regenerative Therapies for Oncology, by Region, Through 2030
Table 20 : Orthopedics and Musculoskeletal Disorders: Tissue Engineeringand Regeneration Product
Table 21 : Global Market for Stem Cell and Regenerative Therapy for Orthopedics, by Region, Through 2030
Table 22 : Global Market for Stem Cell and Regenerative Therapy for Diabetes, by Region, Through 2030
Table 23 : Dermatology: Tissue Engineering and Regeneration Products
Table 24 : Global Market for Stem Cell and Regenerative Therapy for Dermatology, by Region, Through 2030
Table 25 : Global Market for Stem Cell and Regenerative Therapy for CVDs, by Region, Through 2030
Table 26 : Global Market for Stem Cell and Regenerative Therapy for Central Nervous System Disorders, by Region, Through 2030
Table 27 : Global Market for Stem Cell and Regenerative Therapy for Other Applications, by Region, Through 2030
Table 28 : Global Market for Stem Cell and Regenerative Therapy, by Region, Through 2030
Table 29 : North American Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 30 : North American Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 31 : North American Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 32 : North American Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
Table 33 : European Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 34 : European Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 35 : European Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 36 : European Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
Table 37 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 38 : Asia-Pacific Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 39 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 40 : Asia-Pacific Market for Stem Cell and Regenerative Therapy, by Country, Through 2030
Table 41 : RoW Market for Stem Cell and Regenerative Therapy, by Products and Services, Through 2030
Table 42 : RoW Market for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, Through 2030
Table 43 : RoW Market for Stem Cell and Regenerative Therapy, by Application, Through 2030
Table 44 : Leading Players, by Ranking, 2024
Table 45 : Leading Players, by Rank, 2024
Table 46 : Recent Developments in the Stem Cell and Regenerative Therapy Market, 2023-2025
Table 47 : ESG Rankings for Major Stem Cell and Regenerative Therapy Companies, 2025*
Table 48 : ESG: Environmental Overview
Table 49 : ESG: Social Overview
Table 50 : ESG: Governance Overview
Table 51 : Patent Applications Related to Gene Therapy, by Applicant, 2020-2025
Table 52 : Select Patent Grants for Gene Therapy, 2024 and 2025
Table 53 : Patent Applications Related to Cell Therapy, by Applicant, 2020-2025
Table 54 : Select Patents Granted for Cell Therapy, 2024 and 2025
Table 55 : Patent Applications for Tissue Engineering, by Applicant, 2020-2025
Table 56 : Select Patents Granted for Tissue Engineering, 2024 and 2025
Table 57 : Abbreviations Used in the Stem Cell and Regenerative Therapy Market Report
Table 58 : AbbVie Inc.: Company Snapshot
Table 59 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 60 : AbbVie Inc.: Product Portfolio
Table 61 : AbbVie Inc.: News/Key Developments, 2023-2025
Table 62 : Amgen Inc.: Company Snapshot
Table 63 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 64 : Amgen Inc.: Product Portfolio
Table 65 : Amgen Inc.: News/Key Developments, 2024
Table 66 : Biogen: Company Snapshot
Table 67 : Biogen: Financial Performance, FY 2023 and 2024
Table 68 : Biogen: Product Portfolio
Table 69 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Company Snapshot
Table 70 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Financial Performance, FY 2023 and 2024
Table 71 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): Product Portfolio
Table 72 : Bluebird Bio Inc. (Genetix Biotherapeutics Inc.): News/Key Developments, 2022-2025
Table 73 : Bristol-Myers Squibb Co.: Company Snapshot
Table 74 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 75 : Bristol-Myers Squibb Co.: Product Portfolio
Table 76 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 77 : Cellectis S.A.: Company Snapshot
Table 78 : Cellectis S.A.: Financial Performance, FY 2023 and 2024
Table 79 : Cellectis S.A.: Product Portfolio
Table 80 : Cellectis S.A.: News/Key Developments, 2023 and 2024
Table 81 : CRISPR Therapeutics: Company Snapshot
Table 82 : CRISPR Therapeutics: Financial Performance, FY 2023 and 2024
Table 83 : CRISPR Therapeutics: Product Portfolio
Table 84 : CRISPR Therapeutics: News/Key Developments, 2023 and 2024
Table 85 : Eureka Therapeutics Inc.: Company Snapshot
Table 86 : Eureka Therapeutics Inc: Product Portfolio
Table 87 : Eureka Therapeutics Inc.: News/Key Developments, 2023 and 2024
Table 88 : Gilead Sciences Inc.: Company Snapshot
Table 89 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 90 : Gilead Sciences Inc.: Product Portfolio
Table 91 : Gilead Sciences Inc.: News/Key Developments, 2022-2025
Table 92 : MiMedx Group Inc.: Company Snapshot
Table 93 : MiMedx Group Inc.: Financial Performance, FY 2023 and 2024
Table 94 : MiMedx Group Inc.: Product Portfolio
Table 95 : MiMedx Group Inc.: News/Key Developments, 2022-2024
Table 96 : Novartis AG: Company Snapshot
Table 97 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 98 : Novartis AG: Product Portfolio
Table 99 : Novartis AG: News/Key Developments, 2023 and 2024
Table 100 : Organogenesis Inc.: Company Snapshot
Table 101 : Organogenesis Inc.: Financial Performance, FY 2023 and 2024
Table 102 : Organogenesis Inc.: Product Portfolio
Table 103 : Stryker: Company Snapshot
Table 104 : Stryker: Financial Performance, FY 2023 and 2024
Table 105 : Stryker: Product Portfolio
Table 106 : Stryker: News/Key Developments, 2025
Table 107 : Tecnoss: Company Snapshot
Table 108 : Tecnoss: Product Portfolio
Table 109 : Zimmer Biomet: Company Snapshot
Table 110 : Zimmer Biomet: Financial Performance, FY 2023 and 2024
Table 111 : Zimmer Biomet: Product Portfolio

List of Figures

Summary Figure : Global Market Shares for Stem Cell and Regenerative Therapy, by Region, 2024
Figure 1 : Historical Development of CAR T-Cell Therapy
Figure 2 : PESTEL Analysis: Stem Cell and Regenerative Therapy Market
Figure 3 : Porter's Five Forces Analysis: Stem Cell and Regenerative Therapy Market
Figure 4 : Market Dynamics of Stem Cell and Regenerative Therapy
Figure 5 : Number of Scientific Publications on Tissue Engineering, by Year, 2021-2024
Figure 6 : Phases of the R&D Process
Figure 7 : Emerging Technologies in the Stem Cell and Regenerative Therapy Market
Figure 8 : Global Market Shares for Stem Cell and Regenerative Therapy, by Products and Services, 2024
Figure 9 : Global Market Shares for Stem Cell and Regenerative Therapy for Therapeutics, by Product Type, 2024
Figure 10 : Global Market Shares for Stem Cell and Regenerative Therapy, by Application, 2024
Figure 11 : T-Cell Therapy Technique
Figure 12 : Cancer Stem Cell Market, by Type of Cancer
Figure 13 : Global Market Shares for Stem Cell and Regenerative Therapy, by Region, 2024
Figure 14 : North American Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
Figure 15 : U.S. Elderly Population (65 and Older), 2010-2050
Figure 16 : European Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
Figure 17 : Asia-Pacific Market Shares for Stem Cell and Regenerative Therapy, by Country, 2024
Figure 18 : How a Strong ESG Proposition Benefits Businesses
Figure 19 : ESG Pillars
Figure 20 : Patents Granted Related to Gene Therapy, by Year, 2020-2025
Figure 21 : Patent Shares for Gene Therapy Technology, by Document Type, 2020-2025
Figure 22 : Patents Granted Related to Cell Therapy, by Year, 2020-2025
Figure 23 : Patent Shares for Cell Therapy Technology, by Application Status, 2020-2025
Figure 24 : Patents Granted Related to Tissue Engineering, by Year, 2020-2025
Figure 25 : Patents Shares for Tissue Engineering, by Application Status, 2020-2025
Figure 26 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 27 : AbbVie Inc.: Revenue Share, by Region/Country, FY 2024
Figure 28 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 29 : Amgen Inc.: Revenue Share, by Region/Country, FY 2024
Figure 30 : Biogen: Revenue Share, by Business Unit, FY 2024
Figure 31 : Biogen: Revenue Share, by Country/Region, FY 2024
Figure 32 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 33 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 34 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 36 : MiMedx Group Inc.: Revenue Share, by Business Unit, FY 2024
Figure 37 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 38 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 39 : Organogenesis Inc.: Revenue Share, by Business Unit, FY 2024
Figure 40 : Stryker: Revenue Share, by Business Unit, FY 2024
Figure 41 : Stryker: Revenue Share, by Country/Region, FY 2024
Figure 42 : Zimmer Biomet: Revenue Share, by Business Unit, FY 2024
Figure 43 : Zimmer Biomet: Revenue Share, by Country/Region, FY 2024